Had good art prior already (09/716,718)

```
=> d his ful

     (FILE 'HOME' ENTERED AT 15:51:39 ON 02 SEP 2006)

     FILE 'HCAPLUS' ENTERED AT 16:31:36 ON 02 SEP 2006
L15          112 SEA ABB=ON  L14
                 E MUHLRADT PETER/AU
L16           19 SEA ABB=ON  ("MUHLRADT P F"/AU OR "MUHLRADT PETER"/AU OR
                 "MUHLRADT PETER F"/AU)
                 E DEITERS URSULA/AU
L17            5 SEA ABB=ON  "DEITERS URSULA"/AU
L18           22 SEA ABB=ON  L16 OR L17
L19           19 SEA ABB=ON  L18 AND ?LIPOPEPTID?
L20            1 SEA ABB=ON  L19 AND ?WOUND?
                 SELECT RN L20 1

     FILE 'REGISTRY' ENTERED AT 16:35:46 ON 02 SEP 2006
L21            3 SEA ABB=ON  (219986-22-8/BI OR 250718-44-6/BI OR 250718-45-7/BI
                 )

     FILE 'HCAPLUS' ENTERED AT 16:35:51 ON 02 SEP 2006
L22            1 SEA ABB=ON  L20 AND L21
L23            1 SEA ABB=ON  L15 AND L22

     FILE 'REGISTRY' ENTERED AT 16:43:59 ON 02 SEP 2006
L24          874 SEA SSS FUL L13

     FILE 'HCAPLUS' ENTERED AT 16:44:19 ON 02 SEP 2006
L25          349 SEA ABB=ON  L24
L26            3 SEA ABB=ON  L25 AND ?WOUND?
L27            6 SEA ABB=ON  L25 AND (?WOUND? OR ?INJUR?)
L28           40 SEA ABB=ON  L25 AND ?DRUG?(W)?DELIVER?(W)?SYSTEM?
L29           43 SEA ABB=ON  L27 OR L28
L30           31 SEA ABB=ON  L29 AND (PRD<20031230 OR PD<20031230)

     FILE 'USPATFULL' ENTERED AT 16:47:23 ON 02 SEP 2006
L31            6 SEA ABB=ON  L25 AND (?WOUND? OR ?INJUR?)
L32            7 SEA ABB=ON  L29 AND (PRD<20031230 OR PD<20031230)

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 16:47:56 ON 02 SEP 2006
L33           38 DUP REMOV L30 L32 (0 DUPLICATES REMOVED)

     FILE 'REGISTRY' ENTERED AT 16:50:11 ON 02 SEP 2006
L34            1 SEA ABB=ON  250718-44-6/RN

     FILE 'HCAPLUS' ENTERED AT 16:50:20 ON 02 SEP 2006
L35           28 SEA ABB=ON  L34
L36            7 SEA ABB=ON  L30 AND L35
L37           31 SEA ABB=ON  L30 OR L36

     FILE 'USPATFULL' ENTERED AT 16:51:36 ON 02 SEP 2006
L38            7 SEA ABB=ON  L32 OR L36
L39            7 SEA ABB=ON  L37 OR L38

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 16:52:29 ON 02 SEP 2006
L40           38 DUP REMOV L37 L39 (0 DUPLICATES REMOVED)
L41           38 SEA ABB=ON  L33 OR L40

     FILE 'REGISTRY' ENTERED AT 16:54:46 ON 02 SEP 2006
                 SAV L13 AUD033L13/L
```

Use as backup later if needed.

This is MALP-2, the elected specie. Its search is combined with the structure results so it will show up in the printout as a highlighted item.

38 cits from CA Plus or USPatFull

FILE 'HCAPLUS' ENTERED AT 16:55:26 ON 02 SEP 2006
SAV L37 AUD033L37/A

FILE 'USPATFULL' ENTERED AT 16:55:56 ON 02 SEP 2006
SAV L39 AUD033L39/A

FILE HOME

FILE HCAPLUS

FILE COVERS 1907 - 2 Sep 2006 VOL 145 ISS 11
FILE LAST UPDATED: 1 Sep 2006 (20060901/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 SEP 2006 HIGHEST RN 905753-82-4
DICTIONARY FILE UPDATES: 1 SEP 2006 HIGHEST RN 905753-82-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 31 Aug 2006 (20060831/PD)
FILE LAST UPDATED: 31 Aug 2006 (20060831/ED)
HIGHEST GRANTED PATENT NUMBER: US7100210
HIGHEST APPLICATION PUBLICATION NUMBER: US2006195961
CA INDEXING IS CURRENT THROUGH 31 Aug 2006 (20060831/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 31 Aug 2006 (20060831/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2006

Elected specie included in search as RN=250718-44-6

Audet 28/08/2006

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 250718-44-6 REGISTRY
ED Entered STN: 14 Dec 1999
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO03084568 PAGE: 12 claimed protein
CN **MALP 2**
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C99 H167 N19 O30 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

28 REFERENCES IN FILE CA (1907 TO DATE)
28 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 14 Dec 1999

=>

```
=> d que stat l41
L13                 STR
```






```
VAR G1=S/O/CH2
VAR G2=16/18/21
VAR G3=H/CH3
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L24          874 SEA FILE=REGISTRY SSS FUL L13
L25          349 SEA FILE=HCAPLUS ABB=ON  L24
L27            6 SEA FILE=HCAPLUS ABB=ON  L25 AND (?WOUND? OR ?INJUR?)
L28           40 SEA FILE=HCAPLUS ABB=ON  L25 AND ?DRUG?(W)?DELIVER?(W)?SYSTEM?

L29           43 SEA FILE=HCAPLUS ABB=ON  L27 OR L28
L30           31 SEA FILE=HCAPLUS ABB=ON  L29 AND (PRD<20031230 OR PD<20031230)

L32            7 SEA FILE=USPATFULL ABB=ON  L29 AND (PRD<20031230 OR PD<20031230
                 )
L33           38 DUP REMOV L30 L32 (0 DUPLICATES REMOVED)
L34            1 SEA FILE=REGISTRY ABB=ON  250718-44-6/RN
L35           28 SEA FILE=HCAPLUS ABB=ON  L34
L36            7 SEA FILE=HCAPLUS ABB=ON  L30 AND L35
L37           31 SEA FILE=HCAPLUS ABB=ON  L30 OR L36
L38            7 SEA FILE=USPATFULL ABB=ON  L32 OR L36
L39            7 SEA FILE=USPATFULL ABB=ON  L37 OR L38
L40           38 DUP REMOV L37 L39 (0 DUPLICATES REMOVED)
L41           38 SEA L33 OR L40


=> d ibib abs hitstr l41 1-38

L41  ANSWER 1 OF 38  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:582493  HCAPLUS
DOCUMENT NUMBER:          143:103237
TITLE:                    Synergistic adjuvants and antigens encapsulated into
                          liposomes for prophylaxis and therapy
INVENTOR(S):              Konur, Abdo; Graser, Andreas
PATENT ASSIGNEE(S):       Vectron Therapeutics A.-G., Germany
```

SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1550458	A1	20050706	EP 2003-29801	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004308642	A1	20050714	AU 2004-308642	20041222 <--
CA 2544893	AA	20050714	CA 2004-2544893	20041222 <--
WO 2005063288	A1	20050714	WO 2004-EP14630	20041222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-29801 A 20031223 <--
WO 2004-EP14630 W 20041222

AB The present invention relates to liposome, mixts. or liposomes and liposomal compns. comprising at least two different adjuvants and a therapeutic agent, their production and use for the prevention and therapy of proliferative, infectious, vascular, rheumatoid, inflammatory, and immune diseases, in particular autoimmune diseases and allergies. Thus, antitumor effects of Pam3Cys and CpG-PTO ODNs as adjuvants were evaluated in mice inoculated with B16.F1 mouse melanoma cells. The tumor growth after immunization with low doses of antigenic peptide TRP-2 (SVYDFFVWL, 10 μg per animal) encapsulated in AVE3 liposomes (cholesterol/DLPE/DOPS), with or without 2.5 mol% Pam3Cys as liposomal adjuvant, combined with low doses CpG-PTO ODNs (1.3 nmol) in saline or encapsulated into AVE3 was compared. The tumor mass was reduced when mice were immunized with TRP-2 antigen encapsulated in AVE3, with or without 2.5 mol% Pam3Cys plus encapsulated CpG-PTO ODNs 17 days after B16 inoculation, demonstrating that the encapsulation of the CpG-PTO is necessary to achieve a partial tumor rejection. In addition, the application of two encapsulated adjuvants, Pam3Cys and CpG-PTO ODN, further improved antitumor effects, which is in accordance with the synergistic effects observed ex vivo. No significant increase of the survival rate could be achieved with AVE3/TRP-2 plus CpG-PTO in saline. When mice were immunized with AVE3/Pam3Cys/TRP-2 plus CpG-PTO in saline the mean survival time significantly increased to 16 days. When mice were immunized with AVE3/TRP-2, with or without Pam3Cys, plus liposomal CpG-PTO, the mean survival time significantly increased to 19 days. In addition, these data showed that incorporation of Pam3Cys into antigen-carrying AVE3 only significantly increases the survival time when the vaccine setting includes unencapsulated CpG-PTO.

IT **93000-06-7**, Pam3Cys
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant; liposomes containing antigens and synergistic adjuvants for vaccines for prevention and therapy of proliferative, infectious, vascular, inflammatory, and immune diseases)

RN 93000-06-7 HCAPLUS
CN Hexadecanoic acid, (1S)-1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:563466 HCAPLUS
DOCUMENT NUMBER: 143:103152
TITLE: Liposomal vaccine for the treatment of human hematological malignancies
INVENTOR(S): Mueller, Rolf; Graser, Andreas; Konur, Abdo; Mueller-Bruesselbach, Sabine
PATENT ASSIGNEE(S): Vectron Therapeutics Ag, Germany
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1547581	A1	20050629	EP 2003-29802	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004308643	A1	20050714	AU 2004-308643	20041222 <--
CA 2544895	AA	20050714	CA 2004-2544895	20041222 <--
WO 2005063201	A2	20050714	WO 2004-EP14631	20041222 <--
WO 2005063201	A3	20060223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-29802 A 20031223 <--
WO 2004-EP14631 W 20041222

AB The present invention relates to liposomes and compns. comprising liposomes, their production and use for the prevention and therapy of proliferative diseases, infectious diseases, vascular diseases, rheumatoid

diseases, inflammatory diseases, immune diseases, and allergies. Liposomes consisting of two neg. charged phospholipids (PS and PG) in combination with cholesterol can substitute liposomes consisting of cholesterol, PE and either PS or PG.

IT **93000-06-7**, Pam3cys
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomal vaccine for treatment of human hematol. malignancies)

RN 93000-06-7 HCAPLUS

CN Hexadecanoic acid, (1S)-1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:347035 HCAPLUS
DOCUMENT NUMBER: 142:409695
TITLE: The adenylate cyclase virulence factor of Bordetella for the delivery of antigenic peptides to T cells in the treatment of immune-mediated disease
INVENTOR(S): Mills, Kingston Henry Gordon; Boyd, Aoife; Ross, Padraig J.; Lavelle, Edward
PATENT ASSIGNEE(S): The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Ire.
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035557	A2	20050421	WO 2004-IE140	20041014 <--
WO 2005035557	A3	20050728		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004279621	A1	20050421	AU 2004-279621	20041014 <--
CA 2542612	AA	20050421	CA 2004-2542612	20041014 <--
EP 1689772	A2	20060816	EP 2004-770414	20041014 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:	IE 2003-760	A	20031014 <--
	WO 2004-IE140	W	20041014

AB Methods of using the gene cyaA adenylate cyclase of Bordetella to deliver antigens and epitopes to T cells in the treatment and prophylaxis of immune disease are described. These methods may include variants that may be enzymically inactive, and so do not affect cell viability, but can still be transported across the cell membrane. Adenylate cyclase toxin (CyaA) may be combined with self or foreign antigens or peptides derived from them. In expts. with mice, the palmitoylated cyclase did not show non-specific immunostimulatory effects seen with keyhole limpet hemocyanin. Immunostimulation induced the formation of Th2 helper T cells and Tr1 regulatory T cells. Fatty acylation is essential for cell lysis by the cyclase, but does not appear to be essential for immunostimulatory effects. Inoculation using the cyclase with myelin oligodendrocyte peptides in the mouse exptl. autoimmune encephalitis model of multiple sclerosis showed that the inoculation slowed progress of the disease.

IT **93000-06-7**, Pam3Cys
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as Toll-like receptor ligand, adenylate cyclase in immunomodulation using; adenylate cyclase virulence factor of Bordetella for delivery of antigenic peptides to T cells in treatment of immune-mediated disease)

RN 93000-06-7 HCAPLUS

CN Hexadecanoic acid, (1S)-1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 4 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2005:346881 HCAPLUS
DOCUMENT NUMBER:	142:404244
TITLE:	Filamentous hemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
INVENTOR(S):	Mills, Kingston Henry Gordon; McGuirk, Peter; Keogh, Brian
PATENT ASSIGNEE(S):	The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Ire.
SOURCE:	PCT Int. Appl., 82 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034983	A1	20050421	WO 2004-IE139	20041014 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004279209	A1	20050421	AU 2004-279209	20041014 <--
CA 2542593	AA	20050421	CA 2004-2542593	20041014 <--
EP 1677814	A1	20060712	EP 2004-770413	20041014 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			IE 2003-761	A 20031014 <--
			WO 2004-IE139	W 20041014

AB Filamentous hemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof is useful in the prophylaxis and/or treatment of an immune-mediated disorder and/or an autoimmune disease. The FHA may include self or foreign antigens or peptides thereof.

IT **93000-06-7**, Pam3Cys
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(filamentous hemagglutinin from Bordetella in treatment and/or prophylaxis of immune-mediated disorders and combination with toll-like receptor ligands in relation to effects on innate immunity)

RN 93000-06-7 HCAPLUS

CN Hexadecanoic acid, (1S)-1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:259907 HCAPLUS
DOCUMENT NUMBER: 142:334907
TITLE: Nucleic acid vaccines encoding GM-CSF and TLR agonist as adjuvant against infection, cancer, allergy and autoimmune disease
INVENTOR(S): Bembridge, Gary Peter; Craigen, Jennifer L.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005025614	A2	20050324	WO 2004-EP10322	20040913 <--
WO 2005025614	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004271726	A1	20050324	AU 2004-271726	20040913 <--
CA 2538197	AA	20050324	CA 2004-2538197	20040913 <--
EP 1682175	A2	20060726	EP 2004-765233	20040913 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
NO 2006001242	A	20060601	NO 2006-1242	20060317 <--
PRIORITY APPLN. INFO.:			GB 2003-21615 A	20030915 <--
			WO 2004-EP10322 W	20040913

AB The present invention relates to improved nucleic acid vaccines, adjuvant systems, and processes for the preparation of such vaccines and adjuvant systems. In particular, the nucleic acid vaccines and adjuvant systems of the present invention comprise a combination of a nucleotide sequence encoding GM-CSF, or derivs. thereof, and toll-like receptor (TLR) agonists, or derivs. thereof.

IT **112208-04-5**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acid vaccines encoding GM-CSF and TLR agonist as adjuvant against infection, cancer, allergy and autoimmune disease)

RN 112208-04-5 HCAPLUS

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● 3 HCl

PAGE 1-B



L41 ANSWER 6 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:15938 HCAPLUS
DOCUMENT NUMBER: 142:107390
TITLE: Combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases
INVENTOR(S): Carson, Dennis A.; Cottam, Howard B.; Lee, Jongdae
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005004144	A1	20050106	US 2004-824833	20040414 <--
WO 2005016235	A2	20050224	WO 2004-US11566	20040414 <--
WO 2005016235	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-463152P P 20030414 <--

OTHER SOURCE(S): MARPAT 142:107390

AB The present invention provides a broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal and treating diseases such as cancer and autoimmune disease. These agents include TLR-ligands and ligand analogs which induce interferon production, in combination with inhibitors of inosine monophosphate dehydrogenase (IMPDH), that further enhance the induction of interferon production In mice that were injected with 250 μg of 7-thia-8-oxoguanosine (TLR-7 ligand), addition of mizoribine (IMPDH inhibitor) increased levels of Type I interferon in blood more than 4-fold.

IT **87420-41-5**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as TLR ligand; combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases)

RN 87420-41-5 HCAPLUS

CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 7 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1124670 HCAPLUS

DOCUMENT NUMBER: 142:54750

TITLE: Functionally reconstituted viral membranes containing adjuvant

INVENTOR(S): Stegmann, Antonius Johannes Hendrikus; Wilschut, Jan Christiaan; Van Berkum, Johannes Henricus Gerardus

PATENT ASSIGNEE(S): Bestewil Holding B. V., Neth.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110486	A1	20041223	WO 2004-NL437	20040618 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004246974	A1	20041223	AU 2004-246974	20040618 <--
CA 2527735	AA	20041223	CA 2004-2527735	20040618 <--
EP 1633395	A1	20060315	EP 2004-748669	20040618 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1805754	A	20060719	CN 2004-80016758	20040618 <--
BR 2004011519	A	20060801	BR 2004-11519	20040618 <--
US 2006193873	A1	20060831	US 2005-560594	20051213 <--
NO 2005005934	A	20060320	NO 2005-5934	20051214 <--
PRIORITY APPLN. INFO.:			WO 2003-NL450 A	20030619 <--
			WO 2003-NL300450 A	20030619 <--
			WO 2004-NL437 W	20040618

AB The authors disclose methods of forming reconstituted viral membranes with host cell membrane fusion activity. Th reconstituted viral membranes (virosomes) are lipid bilayer membranes containing natural viral lipids and viral fusion protein(s). Pharmaceutical compns. comprising such reconstituted viral membranes, and one or more optional further antigens as well as amphiphilic adjuvants, are also part of the invention. In one example, virosomes, prepared from influenza A virus and a synthetic lipopeptide, are shown to elicit an antibody response when administered via mucosal or i.m. routes.

IT **112208-00-1**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipopeptide-containing virosomes for elicitation of enhanced immune response)

RN 112208-00-1 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **98633-82-0 574741-81-4 697285-24-8**
697285-27-1 697285-28-2 697287-53-9
810676-97-2 810676-98-3 810677-00-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipopeptide-containing virosomes for elicitation of enhanced immune response)
RN 98633-82-0 HCAPLUS
CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 574741-81-4 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Me

RN 697285-24-8 HCAPLUS
CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697285-27-1 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxotetradecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 697285-28-2 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxotetradecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Me

RN 697287-53-9 HCAPLUS
CN L-Glutamic acid, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 810676-97-2 HCAPLUS
CN L-Lysine, N-(1-oxohexadecyl)-S-[3-[[(9Z)-1-oxo-9-octadecenyl]oxy]-2-[[(16Z)-1-oxo-16-pentacosenyl]oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 810676-98-3 HCAPLUS
CN L-Lysine, S-[3-[[(9Z)-1-oxo-9-octadecenyl]oxy]-2-[[(16Z)-1-oxo-16-pentacosenyl]oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 810677-00-0 HCAPLUS
CN L-Proline, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-prolyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Me

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 8 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1054244 HCAPLUS
DOCUMENT NUMBER: 142:28114
TITLE: Therapeutical composition containing dendritic cells and use thereof
INVENTOR(S): Weigt, Henning; Muehlradt, Peter F.; Braun, Armin; Krug, Norbert
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung, Germany
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1484064	A1	20041208	EP 2003-12692	20030604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2524910	AA	20041216	CA 2004-2524910	20040603 <--
WO 2004108145	A1	20041216	WO 2004-EP5996	20040603 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641474	A1	20060405	EP 2004-739563	20040603 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: EP 2003-12692 A 20030604 <--
WO 2004-EP5996 W 20040603

AB The present invention relates to a method for the preparation of a therapeutical composition In particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll-like receptor 2 and/or TLR 6 agonist and using these pretreated dendritic cells for the preparation of a therapeutical composition Moreover, the present invention relates to a therapeutical composition containing dendritic cells and the use thereof for the treatment of various diseases and disorders.

IT **250718-44-6**, Malp-2
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutical composition containing dendritic cells)

RN 250718-44-6 HCAPLUS

CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 9 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:718637 HCAPLUS
DOCUMENT NUMBER: 141:236649
TITLE: Methods for identifying and administering agents that bias the immune response via dendritic cells
INVENTOR(S): Pulendran, Bali; Agrawal, Sudhanshu; Dillon, Stephanie Maree
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074435	A2	20040902	WO 2004-US2773	20040130 <--
WO 2004074435	A3	20050512		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004259790	A1	20041223	US 2004-769635		20040130 <--
PRIORITY APPLN. INFO.:			US 2003-443692P	P	20030130 <--
			US 2003-516169P	P	20031031 <--

AB The invention provides a method of regulating a Th2 immune response which comprises contacting a cell with an amount of a mol. effective to modulate an ERK 1/2 pathway and/or a c-FOS pathway in the cell so as a to regulate the TH2 immune response, which mol. is any of (a) an agonist of a TLR2 (toll-like receptor 2) or a TLR2 variant; (b) an agonist of an intracellular pathway that is initiated by activation of a TLR2; (c) an agonist of an intracellular pathway that is initiated by activation of a receptor activated by SEA (schistosome egg antigen); (d) an antagonist of

an intracellular pathway that opposes TLR2 signaling or activation; (e) an agonist of an ERK 1/2 pathway; (f) an antagonist of a p38 pathway; (g) an antagonist of a JNK 1/2 pathway; or (h) an agonist of the c-FOS pathway, or a mol. that induces c-Fos gene expression, c-Fos mRNA stability, c-Fos protein induction, c-Fos protein stability, or c-Fos protein phosphorylation.

IT **112208-00-1 250718-44-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for identifying and administering agents that bias immune response via dendritic cells)

RN 112208-00-1 HCAPLUS

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 250718-44-6 HCAPLUS

CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L41 ANSWER 10 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:718378 HCAPLUS
DOCUMENT NUMBER: 141:221293
TITLE: A method of diagnosis and treatment of aberrant cells indicating particular diseases by detecting extranuclear nuclear molecules
INVENTOR(S): Brown, Michael Paul
PATENT ASSIGNEE(S): Medvet Science Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073739	A1	20040902	WO 2004-AU223	20040223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212636	A1	20040902	AU 2004-212636	20040223 <--
CA 2516335	AA	20040902	CA 2004-2516335	20040223 <--
EP 1599226	A1	20051130	EP 2004-713491	20040223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1761484	A	20060419	CN 2004-80007259	20040223 <--
JP 2006518453	T2	20060810	JP 2006-501372	20040223 <--
NO 2005004049	A	20051111	NO 2005-4049	20050831 <--
PRIORITY APPLN. INFO.:			AU 2003-900777 A	20030221 <--
			AU 2003-901126 A	20030306 <--
			WO 2004-AU223 A	20040223

AB The present invention relates generally to a method for detecting an aberrant cell, and more particularly an apoptotic cell, in a subject or in a biol. sample from said subject, and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting an apoptotic cell by detecting the presence of extranuclear nuclear mols., in particular La, or a relative increase in extranuclear nuclear mol. levels. The present invention further provides a method for diagnosing or monitoring conditions characterized by aberrant, unwanted or otherwise inappropriate cellular apoptosis in a subject or in a biol. sample from said subject by screening for up-regulation of extranuclear nuclear mol. levels in a cell or group of cells. The present invention provides diagnostic agents useful for detecting these mols. Such diagnostic agents include immunointeractive mols., such as antibodies. Anti-La/SS-B antibody bound apoptotic and necrotic cells.

IT **150496-14-3D**, JBT 3002, conjugates with antibody to nuclear agent, derivs., analogs
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(extranuclear nuclear mols. in diagnosis and treatment of aberrant cells, such as apoptotic cells, indicating particular diseases)
RN 150496-14-3 HCAPLUS

CN L-Glutamamide, S-[(2R)-2,3-bis[(1-oxododecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-N1,N5-bis(2-sulfoethyl)-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

L41 ANSWER 11 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:533958 HCAPLUS
DOCUMENT NUMBER: 141:82330
TITLE: Methods using a lipopeptide or lipoprotein for treating lung infections and lung tumors and for treating and preventing lung metastases
INVENTOR(S): Muhlradt, Peter; Luhrmann, Anke; Tschernig, Thomas; Pabst, Reinhard
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 398,094.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004127405	A1	20040701	US 2003-412547	20030411 <--
DE 10048840	A1	20020411	DE 2000-10048840	20001002 <--
WO 2002028887	A2	20020411	WO 2001-EP11414	20011002 <--
WO 2002028887	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2423897	AA	20041011	CA 2003-2423897		20030411 <--
US 2004249133	A1	20041209	US 2003-398094		20030908 <--
PRIORITY APPLN. INFO.:			DE 2000-10048840	A	20001002 <--
			WO 2001-EP11414	W	20011002 <--
			US 2003-398094	A	20030908 <--
			US 2003-412547	A	20030411 <--

OTHER SOURCE(S): MARPAT 141:82330

AB The invention discloses methods for treating lung infections and lung tumors and treating and preventing metastases of extrapulmonary tumors by administering lipopeptides or lipoproteins having the formula H2NCH[CH2XCH2CH*(OC(O)R2)CH2OC(O)R1]WYCOOH [R1, R2 = C 7-25 alkyl, C 7-25 alkenyl, C 7-25 alkynyl; X = S, O, CH2; W = CO, S(O)n; n = 1, 2; Y = physiol. acceptable amino acid sequence; * denotes asym. carbon atom].

IT **219986-22-8 250718-44-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(lipopeptide or lipoprotein for treating lung infections and lung tumors and for treating and preventing lung metastases)

RN 219986-22-8 HCAPLUS

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-44-6 HCAPLUS
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT 250718-45-7

RL: PAC (Pharmacological activity); BIOL (Biological study)
(lipopeptide or lipoprotein for treating lung infections and lung tumors and for treating and preventing lung metastases)

RN 250718-45-7 HCAPLUS

CN L-Lysine, S-[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L41 ANSWER 12 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:453052 HCAPLUS
DOCUMENT NUMBER: 141:5791
TITLE: Compositions comprising antigen-complexes, method for making same, as well as methods of using the antigen-complexes for vaccination
INVENTOR(S): Stegmann, Antonius Johannes Hendrikus
PATENT ASSIGNEE(S): Crucell Holland B.V., Neth.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045641	A2	20040603	WO 2003-EP13084	20031120 <--
WO 2004045641	A3	20050203		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296592	A1	20040615	AU 2003-296592	20031120 <--
EP 1578443	A2	20050928	EP 2003-811387	20031120 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005214359	A1	20050929	US 2005-128708	20050513 <--
PRIORITY APPLN. INFO.:			EP 2002-102610 A	20021120 <--
			WO 2003-EP50638 A	20030918 <--
			WO 2003-EP13084 W	20031120 <--

AB The present invention provides novel methods and means for the preparation of vaccines that are capable of eliciting strong immune responses, especially through intranasal delivery. The invention discloses particles, referred to as 'co-micelles' in which antigens are present that interact through hydrophobic interactions with certain specific types of amphiphilic compds., wherein said amphiphilic compds. have adjuvant activity and wherein said antigens are preferably antigenic surface proteins, such as

integral membrane proteins from infectious agents like viruses. The amphiphilic compound can be a lipopeptide, glycolipid, or a peptide, and the antigen is an amphiphilic protein from a virus, bacterium, parasite, or tumor cell. Especially preferred are co-micelles composed of influenza virus antigens, preferably hemagglutinin, neuraminidase, and/or the M2 protein.

IT **87420-41-5 98633-82-0 112208-00-1**
574741-81-4 697285-24-8 697285-25-9
697285-26-0 697285-27-1 697285-28-2
697285-31-7 697285-32-8 697287-53-9
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amphiphilic compound; co-micelles composed of an amphiphilic compound with adjuvant activity and an antigen for use in vaccines for infection or cancer or diagnosis)

RN 87420-41-5 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98633-82-0 HCAPLUS
CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112208-00-1 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 574741-81-4 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Me

RN 697285-24-8 HCAPLUS
CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697285-25-9 HCAPLUS
CN L-Lysine, S-[2,3-bis[[(9Z)-1-oxo-9-octadecenyl]oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 697285-26-0 HCAPLUS
CN L-Lysine, S-[2,3-bis[[(9Z)-1-oxo-9-octadecenyl]oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 697285-27-1 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxotetradecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 697285-28-2 HCAPLUS
CN L-Lysine, S-[2,3-bis[(1-oxotetradecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 697285-31-7 HCAPLUS
CN L-Prolinamide, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-prolyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697285-32-8 HCAPLUS
CN L-Histidine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-histidyl-L-histidyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 697287-53-9 HCAPLUS
CN L-Glutamic acid, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L41 ANSWER 13 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:412833 HCAPLUS
DOCUMENT NUMBER: 140:390296
TITLE: Preparation of chemically well-defined carbohydrate dendrimer conjugates
INVENTOR(S): Heegaard, Peter; Boas, Ulrik
PATENT ASSIGNEE(S): Danmarks Fodevare- Og Veterinaerforskning, Den.
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041310	A1	20040521	WO 2003-DK766	20031107 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003275954	A1	20040607	AU 2003-275954	20031107 <--
PRIORITY APPLN. INFO.:			DK 2002-1724 A	20021108 <--
			WO 2003-DK766 W	20031107 <--

AB The authors disclose the synthesis of dendrimer conjugates having a well-defined chemical structure. The conjugates comprise one or more carbohydrate moieties and one or more immunomodulating substances coupled to a dendrimer. First, the carbohydrate is bound to the dendrimer in a chemoselective manner. Subsequently, the immunomodulating substance is also bound in a chemoselective manner, to give a dendrimer conjugate with a well-defined structure and connectivity and containing a precise, pre-determined ratio of carbohydrate to immunomodulating substance. The invention also relates to novel dendrimer conjugates and their use in vaccination, production of antibodies, high throughput screening, diagnostic assays and libraries. In one example, the O antigen of Salmonella typhimurium is conjugated to dendrimers of diaminobutane (DAB) or polyamidoamine (PAMAM).

IT **87420-41-5D**, carbohydrate dendrimer conjugates-containing
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and application of)
RN 87420-41-5 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 14 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:412759 HCAPLUS
DOCUMENT NUMBER: 141:1262
TITLE: Methods of treating pulmonary fibrotic and airway remodeling disorders with Toll-like receptor agonists
INVENTOR(S): Raz, Eyal; Broide, David H.; Takabayashi, Kenji
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004041183	A2	20040521	WO 2003-US34582		20031029 <--
WO 2004041183	A3	20040624			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003287332	A1	20040607	AU 2003-287332		20031029 <--
US 2004248837	A1	20041209	US 2003-697817		20031029 <--
PRIORITY APPLN. INFO.:			US 2002-423035P	P	20021101 <--
			WO 2003-US34582	W	20031029 <--

AB The present invention provides methods of treating airway remodeling, the methods generally involve administering an effective amount of a Toll-like receptor agonist to an individual suffering from airway remodeling. The present invention provides methods of treating pulmonary fibrosis, the methods generally involving administering an effective amount of a Toll-like receptor agonist to an individual in need thereof. The present invention further provides pharmaceutical compns. comprising a TLR agonist and a formulation suitable for delivery by inhalation. Systemic administration of ISS (phosphorothioate 5'-TGACTGTGAACGTTCGAGATGA-3'), a TLR9 agonist, significantly reduced airway responsiveness to MCh in mice repetitively challenged with OVA compared to untreated mice repetitively challenged with OVA.

IT **87420-41-5**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TLR2 ligand, integrin β6 gene transcription inhibition by; Toll-like receptor agonists for treating pulmonary fibrotic and airway remodeling disorders)

RN 87420-41-5 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 15 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:192912 HCAPLUS
DOCUMENT NUMBER: 141:258937
TITLE: Synthetic peptide-based highly immunogenic liposomal constructs
AUTHOR(S): Frisch, Benoit; Roth, Audrey; Schuber, Francis
CORPORATE SOURCE: Laboratoire de Chimie Bioorganique, Faculte de Pharmacie, UMR 7514 CNRS-ULP, Illkirch, 67400, Fr.
SOURCE: Methods in Enzymology (**2003**), 373(Liposomes, Part C), 51-73
CODEN: MENZAU; ISSN: 0076-6879
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A simple liposome preparation that assocs. well-defined B and "universal" T-helper peptide epitopes, both covalently linked to the surface of the same vesicle by means of specific anchors, is described. These totally synthetic liposomal diepitope constructs, which mimic the context of an in vivo antigenic challenge, elicit humoral responses that are characterized by an immunol. memory and by particularly intense and long-lasting T-dependent secondary responses.

IT **213690-36-9DP**, conjugates with peptide epitopes
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic peptide-based highly immunogenic liposomal constructs)

RN 213690-36-9 HCAPLUS
CN Glycinamide, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-alanyl-N-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 16 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:143192 HCAPLUS
DOCUMENT NUMBER: 140:198069
TITLE: Immunogenic lipopeptides comprising T helper and cytotoxic T lymphocyte epitopes for vaccine against Listeria, influenza virus, hepatitis C virus and cancer
INVENTOR(S): Jackson, David; Zeng, Weiguang
PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical Research, Australia
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004014957	A1	20040219	WO 2003-AU1019		20030812 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2494193	AA	20040219	CA 2003-2494193		20030812 <--
AU 2003249778	A1	20040225	AU 2003-249778		20030812 <--
BR 2003013101	A	20050628	BR 2003-13101		20030812 <--
EP 1546206	A1	20050629	EP 2003-783852		20030812 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1688605	A	20051026	CN 2003-824145		20030812 <--
JP 2006513979	T2	20060427	JP 2004-526518		20030812 <--
PRIORITY APPLN. INFO.:			US 2002-403328P	P	20020812 <--
			WO 2003-AU1019	W	20030812 <--

OTHER SOURCE(S): MARPAT 140:198069
AB The present invention provides synthetic immunogenic lipopeptide mols. comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably

the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.

IT **87420-41-5 656831-18-4 656831-19-5 656831-20-8 656831-21-9**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic lipopeptides comprising T helper and cytotoxic T lymphocyte epitopes for vaccine against viral and bacterial infection as well as cancer)

RN 87420-41-5 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-18-4 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-19-5 HCAPLUS
CN Octadecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-20-8 HCAPLUS

CN Octanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-21-9 HCAPLUS
CN Dodecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 17 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:143191 HCAPLUS
DOCUMENT NUMBER: 140:198068
TITLE: Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes for vaccination against infection, fertility, gastric ulcer and tumor
INVENTOR(S): Jackson, David; Zeng, Weiguang
PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical Research, Australia
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014956	A1	20040219	WO 2003-AU1018	20030812 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494192	AA	20040219	CA 2003-2494192		20030812 <--
AU 2003250586	A1	20040225	AU 2003-250586		20030812 <--
EP 1543039	A1	20050622	EP 2003-783851		20030812 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013154	A	20050802	BR 2003-13154		20030812 <--
CN 1688606	A	20051026	CN 2003-824149		20030812 <--
JP 2006513140	T2	20060420	JP 2004-526517		20030812 <--
AU 2006202423	A1	20060629	AU 2006-202423		20060607 <--
PRIORITY APPLN. INFO.:			US 2002-402838P	P	20020812 <--
			WO 2003-AU1018	W	20030812 <--

OTHER SOURCE(S): MARPAT 140:198068

AB The present invention provides synthetic immunogenic lipopeptide mols. comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope. Lipopeptide antigen of influenza virus hemagglutinin, canine distemper virus F protein, viral glycoprotein, Group A Streptococcus M protein, gastrin, pentagastrin, and LHRH are depicted as anti-infective, anti-ulcerative and contraceptive vaccines.

IT **656831-22-0P 656831-24-2P 656831-25-3P**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(immunogenic lipopeptides comprising T-helper epitope and B-cell epitope for vaccination against infection, fertility, gastric ulcer and tumor)

RN 656831-22-0 HCAPLUS

CN Glycine, glycyl-L-alanyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-arginyl-L-phenylalanyl-L-glutaminyl-L-isoleucyl-L-lysylglycyl-L-valyl-L-α-glutamyl-L-leucyl-L-lysyl-L-seryl-N6-[S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl]-L-lysylglycyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



PAGE 4-A





PAGE 5-A





RN 656831-24-2 HCAPLUS
CN L-Phenylalanine, L-lysyl-L-leucyl-L-isoleucyl-L-prolyl-L-asparaginyl-L-alanyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-threonyl-L-lysyl-L-alanyl-L-α-glutamyl-L-leucyl-N6-[S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-seryl]-L-lysylglycyl-L-tryptophyl-L-methionyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-C

RN 656831-25-3 HCAPLUS
CN L-Phenylalanine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-L-seryl-L-seryl-L-lysyl-L-leucyl-L-isoleucyl-L-prolyl-L-asparaginyl-L-alanyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-threonyl-L-lysyl-L-alanyl-L-α-glutamyl-L-leucylglycyl-L-tryptophyl-L-methionyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 1-C



IT **87420-41-5D**, conjugates **656831-18-4D**, conjugates **656831-19-5D**, conjugates **656831-20-8D**, conjugates **656831-21-9D**, conjugates
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic lipopeptides comprising T-helper epitope and B-cell epitope for vaccination against infection, fertility, gastric ulcer and tumor)

RN 87420-41-5 HCAPLUS

CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-18-4 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-19-5 HCAPLUS
CN Octadecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-20-8 HCAPLUS
CN Octanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 656831-21-9 HCAPLUS
CN Dodecanoic acid, 1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 18 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:55397 HCAPLUS
DOCUMENT NUMBER: 140:105268
TITLE: Macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use thereof
INVENTOR(S): Muehlradt, Peter F.; Morr, Michael
PATENT ASSIGNEE(S): GBF Gesellschaft fuer Biotechnologische Forschung MbH, Germany
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1382352	A1	20040121	EP 2002-16066	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2489010	AA	20040129	CA 2003-2489010	20030718 <--
WO 2004009125	A2	20040129	WO 2003-EP7892	20030718 <--
WO 2004009125	A3	20040527		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003251002	A1	20040209	AU 2003-251002		20030718 <--
EP 1521600	A2	20050413	EP 2003-765055		20030718 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2006134061	A1	20060622	US 2005-521013		20050913 <--
PRIORITY APPLN. INFO.:			EP 2002-16066	A	20020719 <--
			WO 2003-EP7892	W	20030718 <--

OTHER SOURCE(S): MARPAT 140:105268

AB The invention discloses bisacyloxypropylcysteine conjugates R2C(O)OCH[R1C(O)OCH2]CH2SCH(NH2)C(O)YR3 (R1, R2 = fatty acid group; Y = NH, O, S, OCO; R3 = conjugate group, especially a polymer). Conjugates of the invention include e.g. S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylene glycol. The conjugates of the invention show good macrophage-stimulating activity and need no other solubilizers. They are useful for numerous applications, particularly for macrophage stimulation, stimulation of antibody production, as a defense against infection, as immunostimulants, particularly in relation to tumors, for the prevention and treatment of septic shock, for **wound** healing, and as adjuvants for vaccines.

IT **647013-57-8**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use)

RN 647013-57-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-(2-aminoethyl)-ω-[2-[[(2R)-3-[[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]thio]-1-oxo-2-[(1-oxohexadecyl)amino]propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $(CH_2)_{14}$ — Me

IT **647013-56-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use)

RN 647013-56-7 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-[2-[[(2R)-2-amino-3-[[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]thio]-1-oxopropyl]amino]ethyl]-ω-(2-aminoethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **210532-98-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use)

RN 210532-98-2 HCAPLUS

CN Hexadecanoic acid, 1-[[[(2S)-2-carboxy-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 19 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818310 HCAPLUS
DOCUMENT NUMBER: 139:306533
TITLE: Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
INVENTOR(S): Guzman, Carlos Alberto; Muehlradt, Peter
PATENT ASSIGNEE(S): GBF Gesellschaft fuer Biotechnologische Forschung m.b.H., Germany
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003084568	A2	20031016	WO 2003-EP3497		20030403 <--
WO 2003084568	A3	20031231			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2480196	AA	20031016	CA 2003-2480196		20030403 <--
AU 2003226777	A1	20031020	AU 2003-226777		20030403 <--
EP 1490106	A2	20041229	EP 2003-745782		20030403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005276813	A1	20051215	US 2004-509917		20041004 <--
PRIORITY APPLN. INFO.:			EP 2002-7640	A	20020404 <--
			WO 2003-EP3497	W	20030403 <--

AB Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-Pr at the amino-terminal cysteine of a peptide or protein, preferably S-(2,3-bispalmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others. The lipopeptides stimulate both Th1 and Th2 cells and IgG and IgA responses to an antigen.

IT **143405-67-8D**, peptide conjugates **250718-44-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine comprising an antigen and lipopeptide or lipoprotein as mucosal adjuvant for stimulation of T-cells and Igs)
RN 143405-67-8 HCAPLUS
CN Hexadecanoic acid, (1R)-1-[[[(2R)-2-amino-2-carboxyethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250718-44-6 HCAPLUS
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L41 ANSWER 20 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:717504 HCAPLUS
DOCUMENT NUMBER: 139:244691
TITLE: Vaccines directed to cancer-associated carbohydrate antigens
INVENTOR(S): Hakomori, Sen-itiroh; Handa, Kazuko
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont. of U.S. Ser. No. 696,213, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003170249	A1	20030911	US 2002-40336	20020109 <--
PRIORITY APPLN. INFO.:			US 1999-253024	B1 19990219 <--
			US 2000-696213	B1 20001026 <--

AB Disclosed are a vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier, such as a bacterial adjuvant or a chemical synthesized adjuvant. The carbohydrate antigen can be Tn or

sialyl-Tn. The invention describes the chemical synthesis of polymeric Tn or sialyl-Tn or of a lactone of same. In one example the authors present the selection of peptide(s) of a specific sequence capable of binding MHC class II or class I proteins, preferably HLA-DR β1 or β2, since the majority of humans carry these mols. When the binding of the specific peptide is verified, it is stabilized and used as a carrier for carbohydrate antigens, especially Tn and sialyl-Tn. Alternatively, peptide mimetics of Tn or sialyl-Tn are bound to such carrier peptides.

IT **98633-82-0DP**, reaction products with Tn antigen-Ser conjugate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccines preparation directed to cancer-associated carbohydrate antigens)

RN 98633-82-0 HCAPLUS

CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 21 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:410518 HCAPLUS
DOCUMENT NUMBER: 140:26635
TITLE: Stimulation of Bronchus-Associated Lymphoid Tissue in Rats by Repeated Inhalation of Aerosolized Lipopeptide MALP-2
AUTHOR(S): Luehrmann, A.; Tschernig, T.; Pabst, R.
CORPORATE SOURCE: Functional and Applied Anatomy, Medical School of Hannover, Hannover, Germany
SOURCE: Pathobiology (**2003**), Volume Date 2002-2003, 70(5), 266-269
CODEN: PATHEF; ISSN: 1015-2008
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: Bronchus-associated lymphoid tissue (BALT) is a part of the integrated mucosal immune system. It may play an important functional role for antigen uptake and induction of specific immune reactions. The aim of this study was to investigate whether it is possible to induce or modulate BALT by the repetitive inhalation of the synthetic lipopeptide MALP-2. Methods: Female Lewis rats (245±19 g) inhaled 25 μg of MALP-2 six times at intervals of 1 wk. One week after the last inhalation, they were sacrificed. Cells of the bronchoalveolar lavage and

the left lung were investigated by flow cytometry. The middle lobe of the right lung was embedded in paraffin. BALT was semiquant. measured in 15 serial cross sections per animal. Results: After repetitive inhalation of the diluent as well as MALP-2, BALT was found. The total area was increased after repetitive treatment with MALP-2. In addition, the preferential incidence of BALT was higher after MALP-2 application, in association with a bronchial diameter of 0.6-1 mm. The cellular anal. revealed no differences in the number of leukocyte subsets between the control and MALP-2 group. Conclusion: MALP-2 is a potent local stimulator and can be used to modulate BALT by repetitive inhalant treatment. The functional significance of enlarged or activated BALT has to be elucidated in future studies.

IT **250718-44-6**, MALP-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stimulation of bronchus-associated lymphoid tissue in rats by repeated inhalation of aerosolized lipopeptide MALP-2)

RN 250718-44-6 HCAPLUS

CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 22 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:927549 HCAPLUS
DOCUMENT NUMBER: 138:23641
TITLE: Alternative splice forms of proteins as basis for multiple therapeutic modalities
INVENTOR(S): Wong, Albert J.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002097044	A2	20021205	WO 2002-US16707	20020528 <--
WO 2002097044	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2448109	AA	20021205	CA 2002-2448109	20020528 <--
US 2003069181	A1	20030410	US 2002-156932	20020528 <--
EP 1401472	A2	20040331	EP 2002-734555	20020528 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1511040	A	20040707	CN 2002-810609	20020528 <--
JP 2005515157	T2	20050526	JP 2003-500213	20020528 <--
PRIORITY APPLN. INFO.:			US 2001-293791P P	20010525 <--
			WO 2002-US16707 W	20020528 <--

AB Peptides or antibodies derived form alternative splice forms of proteins associated with a disease or physiol. condition are used as therapeutic or prophylactic agents. Peptides or antibodies derived from alternative splice forms of the vascular endothelial growth factor (VEGF) family of proteins are particularly useful in preventing or delaying the onset of tumors and inducing tumor regression.

IT **98633-82-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alternative splice forms of VEGF proteins as basis for multiple therapeutic antitumor modalities)

RN 98633-82-0 HCAPLUS

CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 23 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:594693 HCAPLUS
DOCUMENT NUMBER:	137:159335
TITLE:	Anticancer agents containing M161 antigen-derived peptides
INVENTOR(S):	Seya, Tsukasa; Matsumoto, Misako; Naito, Kenichiro
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Japan
SOURCE:	PCT Int. Appl., 60 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060469	A1	20020808	WO 2002-JP578	20020128 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2002308799	A2	20021023	JP 2002-18889	20020128 <--
PRIORITY APPLN. INFO.:			JP 2001-19416	A 20010129 <--

AB Disclosed are medicinal compns. such as anticancer agents, T cell differentiation inductive cytokine-inducing agents, immature dendritic cell maturation-inducing agents and the like which contain an M161 antigen peptide fragment, its prodrug or a salt thereof; and a method of screening a substance useful as an anticancer agent, etc. with the use of M161 antigen, its peptide fragment or a salt thereof. The effect of MALP-2 peptide on immature dendritic cell maturation and IL-12p40 secretion was in vitro tested. A tablet containing MALP-2 10 mg/tablet was prepared for administration with a tablet containing leuprorelin acetate 10 mg/tablet.

IT **250718-44-6**, MALP 2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer agents containing M161 antigen-derived peptides)

RN 250718-44-6 HCAPLUS

CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 24 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:276014 HCAPLUS
DOCUMENT NUMBER: 136:304087
TITLE: Use of lipopeptides or lipoproteins for treating lung infections and lung tumors
INVENTOR(S): Muehlradt, Peter; Luehrmann, Anke; Tschernig, Thomas; Pabst, Reinhard
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung m.b.H. (GBF), Germany
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028887	A2	20020411	WO 2001-EP11414	20011002 <--
WO 2002028887	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10048840	A1	20020411	DE 2000-10048840		20001002 <--
AU 2002020584	A5	20020415	AU 2002-20584		20011002 <--
CA 2424285	AA	20030401	CA 2001-2424285		20011002 <--
EP 1322321	A2	20030702	EP 2001-986301		20011002 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
JP 2004510783	T2	20040408	JP 2002-532469		20011002 <--
US 2004127405	A1	20040701	US 2003-412547		20030411 <--
US 2004249133	A1	20041209	US 2003-398094		20030908 <--
PRIORITY APPLN. INFO.:			DE 2000-10048840	A	20001002 <--
			WO 2001-EP11414	W	20011002 <--
			US 2003-398094	A	20030908 <--

OTHER SOURCE(S): MARPAT 136:304087

AB The invention relates to the use of a lipopeptide or lipoprotein for preventing lung inflammation, for increasing the amount of lymphatic tissue in the bronchial mucosa and for treating lung infections and lung tumors. Said lipopeptide or lipoprotein has the general structure, H2NCH(CH2XCH2CH*(OCOR2)CH2OCOR1)WYCO2H, wherein R1 and R2 can be the same or different and represent C7-25 alkyl, C7-25 alkenyl or C7-25 alkinyl, X represents S, O or CH2, W represents CO or S(O)n (n = 1 or 2) and Y represents a physiol. acceptable amino acid sequence consisting of between 1 and 13 amino acid radicals, and the asym. carbon atom marked with * has the absolute S-configuration when X = S (sulfur).

IT **219986-22-8 250718-45-7**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of lipopeptides or lipoproteins for treating lung infections and lung tumors)

RN 219986-22-8 HCAPLUS

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-45-7 HCAPLUS

CN L-Lysine, S-[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L41 ANSWER 25 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:753094 HCAPLUS
DOCUMENT NUMBER: 131:346566
TITLE: Use of lipopeptides or lipoproteins for **wound** treatment
INVENTOR(S): Muehlradt, Peter; Deiters, Ursula
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung m.b.H. (GBF), Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9959610	A2	19991125	WO 1999-EP3436		19990519	<--
WO 9959610	A3	20000120				
W: AU, CA, JP, US						
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
DE 19822820	A1	19991125	DE 1998-19822820		19980520	<--
CA 2328418	AA	19991125	CA 1999-2328418		19990519	<--
AU 9942643	A1	19991206	AU 1999-42643		19990519	<--
AU 756107	B2	20030102				
EP 1077717	A2	20010228	EP 1999-952073		19990519	<--
EP 1077717	B1	20030723				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI						
JP 2002515446	T2	20020528	JP 2000-549274		19990519	<--
AT 245433	E	20030815	AT 1999-952073		19990519	<--
ES 2203193	T3	20040401	ES 1999-952073		19990519	<--
US 2005192217	A1	20050901	US 2003-748033		20031230	<--
PRIORITY APPLN. INFO.:			DE 1998-19822820	A	19980520	<--
			WO 1999-EP3436	W	19990519	<--
			US 2000-716778	B1	20001120	<--

OTHER SOURCE(S): MARPAT 131:346566

AB A Mycoplasma lipopeptide or lipoprotein which on the N-terminus has a dihydroxypropylcysteine group with 2 possibly long-chain fatty acids linked by esterlike bonds is useful for treatment of **wounds** in humans or other animals. These lipopeptides and lipoproteins and their synthetic analogs stimulate the release of cytokines and prostaglandins by macrophages and induce high titers of chemokines in macrophages. The

lipopeptides may be incorporated into liposomes or attached to a biodegradable carrier. Thus, synthetic R-MALP-2 [S-[2,3-bispalmitoyloxy-(2R)-propyl]cysteinyl-GNNDESNISFKEK] was incorporated into phospholipid-cholesterol liposomes which were resuspended in NaCl and injected i.p. into mice. The injection induced a marked migration of granulocytes and other leukocytes into the peritoneum. Intracutaneous injection of R-MALP-2 induced aggregation of leukocytes and formation of new tissue and blood vessels.

IT **219986-22-8 250718-44-6 250718-45-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of lipopeptides or lipoproteins for **wound** treatment)

RN 219986-22-8 HCAPLUS

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-44-6 HCAPLUS
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-45-7 HCAPLUS

CN L-Lysine, S-[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L41 ANSWER 26 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:653363 HCAPLUS
DOCUMENT NUMBER: 131:281560
TITLE: Peptidic drugs for induction of cytotoxic T-cells and treatment of viral infections
INVENTOR(S): Harrer, Thomas
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19814925	A1	19991007	DE 1998-19814925	19980403 <--
DE 19814925	C2	20001005		
CA 2325345	AA	19991014	CA 1999-2325345	19990401 <--
WO 9951750	A1	19991014	WO 1999-EP2249	19990401 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9937042	A1	19991025	AU 1999-37042	19990401 <--
BR 9909389	A	20001205	BR 1999-9389	19990401 <--
EP 1068331	A1	20010117	EP 1999-919176	19990401 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002510496	T2	20020409	JP 2000-542462	19990401 <--
PRIORITY APPLN. INFO.:			DE 1998-19814925 A	19980403 <--
			WO 1999-EP2249 W	19990401 <--

OTHER SOURCE(S): MARPAT 131:281560

AB A medicine is disclosed for the induction of cytotoxic T-cells. The medicine comprises a amino acid sequence X1YX2DDX3 (X1, X3 = one or more of any amino acid; Y = Tyr; X2 = Val, Ile, Leu; D = Asp) or a nucleic acid sequence encoding such an amino acid sequence. The compds. of the invention are useful for the prevention and treatment of viral infections.

IT **98633-82-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidic drugs for induction of cytotoxic T-cells and treatment of viral infections)

RN 98633-82-0 HCAPLUS

CN L-Serine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 27 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:454837 HCAPLUS

DOCUMENT NUMBER: 131:241716

TITLE: Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes

AUTHOR(S): Boeckler, Christophe; Dautel, Dominique; Schelte, Philippe; Frisch, Benoit; Wachsmann, Dominique; Klein, Jean-Paul; Schuber, Francis

CORPORATE SOURCE: Laboratoire Chimie Bioorganique, Faculte Pharmacie, Univ. Louis Pasteur, Illkirch, F-67400, Fr.

SOURCE: European Journal of Immunology (**1999**), 29(7), 2297-2308
CODEN: EJIMAF; ISSN: 0014-2980

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors have designed liposomal diepitope constructs that allow the phys. combination, within the same vesicle, of B and Th epitopes as structurally sep. entities. The immune response against such constructs was explored using TPEDPTDPTDPQDPSS (TPE), a B cell epitope originating from a Streptococcus mutans surface adhesin and QYIKANSKFIGITEL (QYI), a "universal" Th epitope from tetanus toxin. The 2 peptides were linked to the outer surface of small (diameter 100 nm) unilamellar liposomes by covalent conjugation to 2 different anchors. To that end the authors have developed a strategy that allows the controlled chemical coupling of TPE and QYI, functionalized at their N terminus with a thiol, to preformed liposomes containing thiol-reactive derivs. of phosphatidylethanolamine and the lipopeptide S-[2,3-bis (palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-

cysteinyl-alanyl-glycine (Pam3CAG), resp. This synthetic construct (administered i.p. to BALB/c mice) induced highly intense (titers >20000), anamnestic, and long-lasting (>2 yr) immune responses, indicating that this strategy is successful. 2 Parameters were of prime importance to elicit this response with our liposomal diepitope constructs: (1) the simultaneous expression of B and Th epitopes on the same vesicle, and (2) the lipopeptide Pam3CAG anchor of the Th epitope QYI could not be replaced by a phosphatidylethanolamine anchor (a lesser immune response was observed). Anal. of the antibody response revealed a complex pattern; thus, besides the humoral response (production of IgG1, IgG2a, IgG2b) a superposition of a T-independent (TI-2 type) response was also found (IgM and IgG3). These results indicate that liposomal diepitope constructs could be attractive in the development of synthetic peptide-based vaccines.

IT **117858-54-5**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(diepitope combining B and Th cell peptide epitopes to preformed liposomes containing thiol-reactive derivs. of phosphatidylethanolamine and PAM3CAG)

RN 117858-54-5 HCAPLUS
CN Glycine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **244236-02-0**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(thiol-reactive derivs. of phosphatidylethanolamine for liposomes design from B and Th cell peptide epitopes and Pam3CAG)

RN 244236-02-0 HCAPLUS
CN Glycinamide, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-D-cysteinyl-L-alanyl-N-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 28 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:454255 HCAPLUS
DOCUMENT NUMBER: 131:92524
TITLE: Therapeutic liposome-encapsulated immunomodulators
INVENTOR(S): Spitler, Lynn E.; Fidler, Issaiah J.
PATENT ASSIGNEE(S): Jenner Biotherapies, Inc., USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9935162	A1	19990715	WO 1999-US272		19990106 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9922141	A1	19990726	AU 1999-22141		19990106 <--
US 2003017976	A1	20030123	US 2001-764546		20010117 <--
US 2004146552	A1	20040729	US 2003-705618		20031110 <--
PRIORITY APPLN. INFO.:			US 1998-70717P	P	19980107 <--
			US 1999-226075	B1	19990106 <--
			WO 1999-US272	W	19990106 <--
			US 2001-764546	A1	20010117 <--

AB The present invention relates to the use of novel compns. of lipopeptides

that are immunomodulators encapsulated as liposomes or free-form for the treatment of neoplasia and in reducing chemotherapeutically induced cellular pathol., including mucositis. These lipopeptides may be administered alone or in combination with a second antineoplastic agent. E.g., a synthetic JBT 3002 lipopeptide entrapped in phosphatidylcholine/phosphatidylserine liposomes is shown to be a potent activator of tumoricidal properties of murine macrophages by a mechanism that differs from that of lipopolysaccharides. These data highly support the in vivo use of multilamellar liposome-encapsulated JBT 3002 to enhance host resistance to infections and cancer.

IT **93909-73-0**, CGP 31362 **150496-14-3**, JBT 3002
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(free or liposome-encapsulated lipopeptide immunomodulators for tumor treatment and reduction of antitumor adverse effects)

RN 93909-73-0 HCAPLUS
CN Glycinamide, S-[(2R)-2,3-bis[(1-oxododecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-alanyl-D-α-glutaminyl-N-(2-sulfoethyl)-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 150496-14-3 HCAPLUS
CN L-Glutamamide, S-[(2R)-2,3-bis[(1-oxododecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-N1,N5-bis(2-sulfoethyl)-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 29 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:692555 HCAPLUS
DOCUMENT NUMBER: 130:94426
TITLE: Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes
AUTHOR(S): Eue, Ines; Kumar, Rakesh; Dong, Zhongyun; Killion, Jerald J.; Fidler, Isaiah J.
CORPORATE SOURCE: Department of Cell Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SOURCE: Journal of Immunotherapy (**1998**), 21(5), 340-351
CODEN: JOIMF8; ISSN: 1053-8550
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We studied activation to the tumoricidal state of murine peritoneal macrophages by liposomes containing a new synthetic analog, JBT3002, of a lipoprotein from the outer wall of a gram-neg. bacterium. The liposomes containing JBT3002 or CGP31362 were superior to liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) for tumoricidal activation in three ways. First, efficient macrophage activation required lower concns. of JBT3002 or CGP31362 than MTP-PE. Second, macrophage activation by JBT3002 was less dependent on priming by interferon-γ. Third, MLV-JBT3002 activated tumoricidal properties in both lipopolysaccharide (LPS)-responsive and LPS-nonresponsive macrophages. The activation of tumoricidal properties by MLV-JBT3002 depended on protein tyrosine kinase (PTK) activity associated with phosphorylation of tyrosine. The major mechanism for tumoricidal activity in macrophages incubated with MLV-JBT3002 was due to increased activity of inducible nitric oxide synthase (iNOS) and, hence, production of nitric oxide (NO). We base this conclusion on the results of several expts. First, MLV-JBT3002 was not directly toxic to tumor target cells. Second, the specific iNOS inhibitor NG-monomethyl-L-arginine abrogated tumor cell lysis by MLV-JBT3002-treated macrophages. Third, macrophages from iNOS knockout mice did not lyse

tumor cells, even after incubation with high concns. of MLV-JBT3002. These data suggest that liposomes containing the synthetic bacterial lipopeptide JBT3002 are potent activators of macrophage tumoricidal properties.

IT **150496-14-3**, JBT3002
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes)

RN 150496-14-3 HCAPLUS

CN L-Glutamamide, S-[(2R)-2,3-bis[(1-oxododecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-N1,N5-bis(2-sulfoethyl)-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 30 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1997:565095 HCAPLUS
DOCUMENT NUMBER:	127:239117
TITLE:	Cationic lipids and liposomes containing them as drug delivery agents
INVENTOR(S):	Sourovoi, Andrej; Jung, Guenther
PATENT ASSIGNEE(S):	Germany
SOURCE:	Ger. Offen., 20 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19605175	A1	19970814	DE 1996-19605175	19960213 <--

CA 2246456	AA	19970821	CA 1997-2246456	19970212 <--	
CA 2246456	C	20040720			
WO 9730024	A2	19970821	WO 1997-EP629	19970212 <--	
WO 9730024	A3	19970925			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9717240	A1	19970902	AU 1997-17240	19970212 <--	
AU 713039	B2	19991118			
EP 883602	A2	19981216	EP 1997-904417	19970212 <--	
EP 883602	B1	20020904			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 11506795	T2	19990615	JP 1997-528976	19970212 <--	
JP 3525393	B2	20040510			
AT 223374	E	20020915	AT 1997-904417	19970212 <--	
PT 883602	T	20030131	PT 1997-904417	19970212 <--	
ES 2183133	T3	20030316	ES 1997-904417	19970212 <--	
US 6458381	B1	20021001	US 1998-125138	19981014 <--	
PRIORITY APPLN. INFO.:			DE 1996-19605175	A 19960213 <--	
			WO 1997-EP629	W 19970212 <--	

AB Lipophilic amine salts and quaternary ammonium compds. R3R4R5N+CH(W)YN[(CH2)nZR1](CH2)nZR2 X- [I; R1, R2 = C6-24 alkyl, alkenyl, or alkynyl; R3-R5 = H, C1-8 alkyl or aminoalkyl, amino acyl, peptidyl; W = H, CO2H, amino acid side chain, etc.; Y = C(O), (CH2)mC(O), (CH2)m, [CH(OH)CH2]m, CH2S(O)pCH2, SO2, etc.; Z = ester, ether, or amide group; X = anion; m = 1-20; n = 1-8; p = 0-2] form complexes with polyanions, especially with DNA, RNA, or peptides, and are useful, alone or as components of liposomes, for transport of biol. active polyanionic compds. across biol. membranes. I-polyanion complexes may also form ternary complexes with polycations and may be used similarly for transport of polycationic compds. Thus, Boc-Lys(Boc)-OH (Boc = Me3CO2C) was amidated with diethanolamine, esterified with oleoyl chloride, and deprotected to form L-lysine bis(O,O'-oleoyl-β-hydroxyethyl)amide-Dihydrochloride (II). Complexation of II with calf thymus DNA was demonstrated by quenching of the fluorescence of a DNA-ethidium bromide complex. HeLa cells were transformed with a complex of II and plasmid pCMVL DNA (containing the luciferase gene under the control of the cytomegalovirus promoter) 6-fold more efficiently than the same DNA complexes with (dioleoyloxypropyl)trimethylammonium methosulfate.

IT **87420-41-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic lipids and liposomes containing them as drug delivery agents)

RN 87420-41-5 HCAPLUS

CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 31 OF 38 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:15525 HCAPLUS
DOCUMENT NUMBER: 126:73781
TITLE: Multiple antigenic peptide system having adjuvant properties for use in vaccines
INVENTOR(S): Tam, James P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 24 pp., Cont. of U.S. Ser. No. 877,613,abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5580563	A	19961203	US 1994-331489	19941228 <--
WO 9322343	A1	19931111	WO 1993-US4179	19930503 <--

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1992-877613 B2 19920501 <--
WO 1993-US4179 W 19930503 <--

AB A multiple antigenic peptide system is disclosed that comprises a dendritic core and peptides and a lipophilic anchoring moiety. This peptide system is capable of eliciting an immune response when injected into a mammal; vaccines prepared from the system and methods of use including therapeutic protocols are included. This combination eliminates the need for the inclusion of adjuvants found to be toxic to humans, and facilitates the exponential amplification of the antigenic potential of a vaccine prepared therefrom, as noncovalent amplification by a liposome or micellar form is possible. Further, multiple different antigenic peptides may be attached so that the system may be prepared for administration to concurrently treat diverse ailments, e.g. AIDS and influenza. Thus, 4 copies of a 24-residue peptide (designated B1) of the V3 loop of HIV-1 gp120 were linked to the free Nα and Nε positions of Nα,Nε-dilysyl-Lys-Ser-Ser-[Nε-(tripalmitoyl-S-glycerylcysteinyl)]lysyl-alanine, and the product was incorporated into liposomes which were used to immunize mice. The immunized mice showed a high-titer humoral antibody response, a mitogenic response in spleen cells, a CD4+ T-helper cell response, a cytotoxic T-lymphocyte response, and formation of IL-2 by spleen cells after restimulation.

IT **87420-41-5DP**, conjugates with peptides **155382-51-7DP**, conjugates with peptides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multiple antigenic peptide system having adjuvant properties for use

in vaccines)
RN 87420-41-5 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155382-51-7 HCAPLUS
CN Hexadecanoic acid, 1-[[(2-amino-2-carboxyethyl)thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



IT **155382-49-3P 155382-50-6P 155412-14-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multiple antigenic peptide system having adjuvant properties for use in vaccines)
RN 155382-49-3 HCAPLUS
CN L-Cysteine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155382-50-6 HCAPLUS
CN L-Alanine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-3-(2-pyridinyldithio)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155412-14-9 HCAPLUS
CN L-Cysteine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-, methyl ester, bimol. (2→2')-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L41 ANSWER 32 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:203080 USPATFULL
TITLE: Immunostimulatory G, U-containing oligoribonucleotides

INVENTOR(S): Lipford, Grayson, Watertown, MA, UNITED STATES
Bauer, Stefan, Munich, GERMANY, FEDERAL REPUBLIC OF
Wagner, Hermann, Eching, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006172966	A1	20060803
APPLICATION INFO.:	US 2006-368333	A1	20060303 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-407952, filed on 4 Apr 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-421966P	20021029 (60)	<--
	US 2002-370515P	20020404 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1-128
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 7604

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **112208-00-1**
(immunostimulatory G,U-containing oligoribonucleotides, compns., and screening methods)

RN 112208-00-1 USPATFULL

CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L41 ANSWER 33 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2006:158532 USPATFULL			
TITLE:	Bisacyloxypropylcysteine conjugates and the use thereof			
INVENTOR(S):	Muhlradt, Peter, Braunschweig, GERMANY, FEDERAL REPUBLIC OF Morr, Michael, Wolfenbuttel, GERMANY, FEDERAL REPUBLIC OF			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006134061	A1	20060622	
APPLICATION INFO.:	US 2003-521013	A1	20030718	(10)
	WO 2003-EP7892		20030718	
			20050913	PCT 371 date
	NUMBER		DATE	
PRIORITY INFORMATION:	EP 2002-16066		20020719	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190, US			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	6 Drawing Page(s)			
LINE COUNT:	489			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel lipopeptide conjugates, in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The novel conjugates exhibit an excellent macrophage stimulant action and do not require additional solutizing. They can be used in a wide range of applications, in particular for stimulating macrophages, for stimulating antibody synthesis, for combating infection, as an immunostimulant, in particular in relation to tumours, for preventing and treating septicaemic shock, for **wound** healing and as an adjuvant for vaccines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **647013-57-8**

(macrophage-stimulating bisacyloxypropylcysteine conjugates and

therapeutic use)
RN 647013-57-8 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-(2-aminoethyl)-ω-[2-[[(2R)-3-[[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]thio]-1-oxo-2-[(1-oxohexadecyl)amino]propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $(CH_2)_{14}$ — Me

IT **647013-56-7P**
(macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use)
RN 647013-56-7 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-[2-[[(2R)-2-amino-3-[[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]thio]-1-oxopropyl]amino]ethyl]-ω-(2-aminoethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A





IT **210532-98-2**
(macrophage-stimulating bisacyloxypropylcysteine conjugates and therapeutic use)
RN 210532-98-2 USPATFULL
CN Hexadecanoic acid, 1-[[[(2S)-2-carboxy-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 34 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2005:221480 USPATFULL
TITLE: Utilization of lipopeptides or lipoproteins in **wound** treatment and infection prophylaxis
INVENTOR(S): Muhlradt, Peter, Braunschweig, GERMANY, FEDERAL REPUBLIC OF
Deiters, Ursula, Braunschweig, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005192217	A1	20050901
APPLICATION INFO.:	US 2003-748033	A1	20031230 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-716778, filed on 20 Nov 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-EP3436, filed on 19 May 1999, UNKNOWN

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 1998-19822820	19980520	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN LLP, 233 S. WACKER DRIVE, SUITE 6300, SEARS TOWER, CHICAGO, IL, 60606, US

NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns a pharmaceutical preparation for the treatment of **wounds** in animals or humans containing or consisting of a lipopeptide or lipoprotein which carries at the N-terminals a dihydroxypropyl-cysteine group with two, optionally long-chain, fatty acids bonded via ester bonds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **219986-22-8 250718-44-6 250718-45-7**
(use of lipopeptides or lipoproteins for wound treatment)
RN 219986-22-8 USPATFULL
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-44-6 USPATFULL
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 250718-45-7 USPATFULL

CN L-Lysine, S-[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L41 ANSWER 35 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2004:315161 USPATFULL
TITLE:	Methods of treating pulmonary fibrotic disorders
INVENTOR(S):	Raz, Eyal, Del Mar, CA, UNITED STATES Broide, David, San Diego, CA, UNITED STATES Takabayashi, Kenji, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004248837	A1	20041209	
APPLICATION INFO.:	US 2003-697817	A1	20031029	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-423035P	20021101 (60)	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVE, SUITE 200, EAST PALO ALTO, CA, 94303
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	2304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of treating airway remodeling, the methods generally involve administering an effective amount of a Toll-like receptor agonist to an individual suffering from airway remodeling. The present invention provides methods of treating pulmonary fibrosis, the methods generally involving administering an effective amount of a Toll-like receptor agonist to an individual in need thereof. The present invention further provides pharmaceutical compositions comprising a TLR agonist and a formulation suitable for delivery by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **87420-41-5**
(TLR2 ligand, integrin β6 gene transcription inhibition by; Toll-like receptor agonists for treating pulmonary fibrotic and airway remodeling disorders)

RN 87420-41-5 USPATFULL

CN Hexadecanoic acid, 1-[[[(2R)-2-carboxy-2-[(1-oxohexadecyl)amino]ethyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 36 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:184067 USPATFULL
TITLE: Immunostimulatory combinations
INVENTOR(S): Noelle, Randolph J., Plainfield, NH, UNITED STATES
Ahonen, Cory L., Hanover, NH, UNITED STATES
Kedl, Ross M., Roseville, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004141950	A1	20040722
APPLICATION INFO.:	US 2003-748010	A1	20031230 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-437398P	20021230 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **250718-44-6**, MALP-2
(vaccines comprising TLR agonist, TNF/TNFR agonist and antigen for inducing cellular immune response against infection or tumor)
RN 250718-44-6 USPATFULL
CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L41 ANSWER 37 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:329863 USPATFULL
TITLE: Immunostimulatory G, U-containing oligoribonucleotides
INVENTOR(S): Lipford, Grayson, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
Bauer, Stefan, Muenchen, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003232074	A1	20031218	<--
APPLICATION INFO.:	US 2003-407952	A1	20030404 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-370515P	20020404 (60)	<--
	US 2002-421966P	20021029 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211
NUMBER OF CLAIMS: 128
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 7905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **112208-00-1**
(immunostimulatory G,U-containing oligoribonucleotides, compns., and screening methods)
RN 112208-00-1 USPATFULL
CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L41 ANSWER 38 OF 38 USPATFULL on STN

ACCESSION NUMBER:	1999:4651 USPATFULL
TITLE:	Carbohydrate conjugates as inhibitors of cell adhesion
INVENTOR(S):	Kretzschmar, Gerhard, Eschborn, Germany, Federal Republic of Schmidt, Wolfgang, Frankfurt, Germany, Federal Republic of Sprengard, Ulrich, Mainz, Germany, Federal Republic of Bartnik, Eckart, Wiesbaden, Germany, Federal Republic of Seiffge, Dirk, Mainz-Kostheim, Germany, Federal Republic of Kunz, Horst, Mainz, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Hoechst Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5858994		19990112	<--
APPLICATION INFO.:	US 1995-509079		19950731	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 1994-4436164	19941010	<--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	LeGuyader, John L.
ASSISTANT EXAMINER:	Shibuya, Mark L.
LEGAL REPRESENTATIVE:	Foley & Lardner
NUMBER OF CLAIMS:	34
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT:	1747

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel conjugates of tetrasaccharides, preferably of sialyl-Lewis X (SLeX) and sialyl-Lewis A (SLeA), having improved activity as inhibitors of cell adhesion, a process for the preparation of these compounds, and their use as pharmacological active compounds and as diagnostics and pharmaceuticals which contain these conjugates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **177485-19-7P 177485-22-2P**
(preparation of tetrasaccharide conjugates as inhibitors of cell adhesion)

RN 177485-19-7 USPATFULL

CN L-Serinamide, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 177485-22-2 USPATFULL

CN Hexadecanoic acid, 1-[[[3-[[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]hexyl]amino]-3-oxo-2-[(1-oxohexadecyl)amino]propyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **177606-26-7**
(preparation of tetrasaccharide conjugates as inhibitors of cell adhesion)
RN 177606-26-7 USPATFULL
CN Hexadecanoic acid, 1-[[[3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxo-2-[(1-oxohexadecyl)amino]propyl]thio]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



IT **177485-27-7P**
(preparation of tetrasaccharide conjugates as inhibitors of cell adhesion)
RN 177485-27-7 USPATFULL
CN Glycinamide, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-N-(1-oxohexadecyl)-L-cysteinyl-L-alanyl-N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



PAGE 2-B